Down syndrome drug trial asks participants: how did it feel?

NCT ID NCT07413224

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Aelis Farma Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows up on a previous trial of the drug AEF0217 in people with Down syndrome. Researchers are asking participants and their caregivers to share their impressions of the treatment through a simple questionnaire. The goal is to understand what changes, if any, people noticed during the trial. Only 28 people who completed the earlier study are invited to take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AEF0217
What this could lead to: If this study shows that participants noticed meaningful changes, it could help design better future trials for Down syndrome treatments.
What could go wrong: This is a very small, exploratory study that only collects opinions, not hard evidence. It cannot prove the drug works or is safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DOWN SYNDROME (TRISOMY 21) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Down syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DOWN SYNDROME (TRISOMY 21)

Contacts and locations

Locations

Hospital del Mar Research Institute

Barcelona, 08003, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.